Cue Biopharma Brings Autoimmune Back To The Fore With Ono Deal
Executive Summary
Deal Snapshot: Cue’s pipeline is heavy on oncology, but it partnered with Merck on autoimmune in 2017 and while that work has shifted to cancer, the Ono partnership puts the focus back on autoimmune disease.
You may also be interested in...
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Deal Watch: Ionis Out-Licenses Pair Of Generation 2.5 Antisense Candidates
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
What Could Come After CAR-T? Cue Is Betting On Selective Biologics
Emerging Company Profile: Cue Biopharma, a young biotech formed on the basis of research from the Albert Einstein College of Medicine, is developing biologics engineered to selectively modulate disease-relevant T-cells to treat cancer – technology it has called the "next wave" in cancer immunotherapy.